Patients with treated solid tumours (TSTs) are a highly heterogeneous population that differ on the basis of cancer type, including stage and tissue of origin, mutational status of cancer, cancer prognosis and cancer treatment received.

Use of systemic psoriasis therapies in these patients is hindered by concerns about the possibility of augmenting cancer recurrence/progression or infectious complications.

Given the limited direct evidence to answer the clinical question, the present guidance document uses an inference-based approach to explore the risks and benefits imposed on patients with a history of TSTs when their psoriasis is treated with systemic psoriasis therapies to provide a structured framework that helps guide treatment decisions.

This framework supports a discussion between healthcare professionals and their patients about the risks and benefits of systemic psoriasis therapy in patients with previously TSTs.

The initiation of systemic psoriasis therapy after cancer treatment largely depends on immune reconstitution post-cancer treatment that depends primarily on the type of cancer treatment received rather than on the type of solid tumour or other factors (stage, mutational status, etc.).